Anti-MDM2 Antibody, clone Z6H3 ZooMAb^® Rabbit Monoclonal

rabbit

200

expressed in HEK 293 cells

unconjugated

purified antibody

primary antibodies

Z6H3, recombinant monoclonal

recombinant, expressed in HEK 293 cells

ZooMAb^® learn more

lyophilized

calculated mol wt 55.23 kDa
observed mol wt ~58 kDa

mouse, human

antibody small pack of 25 μL

recombinant expression
Learn more about Antibody Enhanced Validation

affinity binding assay: suitable
immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable
western blot: suitable

IgG

N-terminal half

NP_001354919

Q00987

ambient

2-8℃

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies.

Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Learn more about ZooMAb here.

Clone Z6H3 is a ZooMAb^® rabbit recombinant monoclonal antibody that specifically detects MDM2. It targets an epitope within 14 amino acids from the N-terminal half.

KLH-conjugate linear peptide corresponding to 14 amino acids from the N-terminal half of human E3 ubiquitin-protein ligase Mdm2 (MDM2).

Anti-MDM2, clone Z6H3 ZooMAb^®, Cat. No. ZRB1127, is a recombinant Rabbit monoclonal antibody that specifically detects MDM2 and is tested for use in Affinity Binding Assay, Immunohistochemistry (Paraffin), and Western Blotting.
Quality Control Testing

Evaluated by Western Blotting in Mouse brain nuclear extract.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected MDM2 in Mouse brain nuclear extract.

Tested applications

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected MDM2 in human brain tissue sections.

Affinity Binding Assay: A representative lot of this antibody bound MDM2 with a KD of 8.3 x 10-8 in an affinity binding assay.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.

300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

E3 ubiquitin-protein ligase Mdm2 (UniProt: Q00987; also known as EC:2.3.2.27, Double minute 2 protein, Hdm2, Oncoprotein Mdm2, RING-type E3 ubiquitin transferase, Mdm2, p53-binding protein Mdm2) is encoded by the MDM2 gene (Gene ID: 4193) in human. Mdm2 is a ubiquitously expressed, p53-inducible phosphoprotein protein that is predominantly expressed in the nucleoplasm. It binds to the N-terminus of the p53 and negatively regulates its activity. as an E3 ligase to ubiquitinate p53 and force its export from the nucleus to the cytoplasm where it is degraded in the proteasome. Over-expression of MDM2 is reported in several cancers, including breast cancer and soft tissue carcinomas. In breast cancer its over-expression is also correlated with lack of p21 expression. MDM2 overexpression is also associated with chemotherapeutic resistance in human malignancies. The mechanisms of chemotherapeutic resistance by MDM2 overexpression includes both the p53-MDM2 loop-dependent and p53-MDM2 loop-independent pathways. In normal cells, its over-expression causes G1 phase arrest. Hence, in normal cells it may have a protective role in preventing untimely cell cycle progression. MDM2 can underdo phosphorylation on serine 166 by SGK1 and at multiple sites near the RING domain (aa 438-479) by ATM kinase upon DNA damage. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Hou, H., et al. (2019). Cancer Cell Int. 19; Article 216).

Recommend storage of lyophilized product at 2-8℃; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8℃, or -20℃ for long term storage. Avoid repeated freeze-thaws.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

11 - Combustible Solids

WGK 1